Literature DB >> 19840249

Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model.

Sven Francque1, Sam Wamutu, Shyama Chatterjee, Eric Van Marck, Arnold Herman, Albert Ramon, Alexander Jung, Wim Vermeulen, Benedicte De Winter, Paul Pelckmans, Peter Michielsen.   

Abstract

INTRODUCTION: Steatosis, without fibrosis, may lead to changes in liver blood flow, which are poorly understood, and to date have not been correlated to portal pressure and related haemodynamics. AIMS: To study the temporal relation between progressive steatosis, portal pressure, systemic haemodynamics, vascular responsiveness, mesenteric and portal blood flow in methionine-choline-deficient diet (MCDD)-fed rats.
METHODS: Male Wistar rats fed the MCDD were examined at week (w) 0-1-2-3-4-5-6-7-8, respectively, including systemic haemodynamics and portal pressure. At w0-4-8, in vivo blood flow was measured in the portal vein and the superior mesenteric artery. Dose-response curves to phenylephrine (PE) were established in abdominal aortic rings.
RESULTS: Histology showed 100% steatosis from w3 on. Fibrosis was absent. Significant inflammation was nearly absent upon w4. Portal pressure slightly increased at w2, reached a maximum at w4 [9.4 +/- 0.3 vs 2.9 +/- 0.6 mmHg at w0 (P=0.003)] and remained stable upon w8. Mean arterial blood pressure (MABP) decreased from w2 on [98.7 +/- 5.7 mmHg on w4 compared with 123.8 +/- 1.8 on w0 (P=0.002)]. Portal flow increased from 1.85 +/- 0.11 to 3.07 +/- 0.44 ml/min/100 g on w0 and w8 respectively (P=0.039). Mesenteric artery flow increased from 3.40 +/- 0.26 to 4.56 +/- 0.30 ml/min/100 g on w0 and w8 respectively (P=0.043). Vascular responsiveness to PE gradually decreased from 138 +/- 3% on w0 to 110 +/- 5% on w4 (P=0.013).
CONCLUSION: Steatohepatitis induces significant portal hypertension (PHT) in the absence of fibrosis, associated with an increase in mesenteric arterial and portal venous flow, arterial hyporesponsiveness to vasoconstrictors and a decrease in MABP, indicating the presence of splanchnic vasodilation and hyperdynamic circulation. These alterations resemble those seen in cirrhotic PHT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19840249     DOI: 10.1111/j.1478-3231.2009.02136.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  12 in total

Review 1.  Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease.

Authors:  Gyorgy Baffy
Journal:  Dig Dis Sci       Date:  2018-01-22       Impact factor: 3.199

2.  Liver resection and metabolic disorders: an undescribed mechanism leading to postoperative mortality.

Authors:  Alban Zarzavadjian Le Bian; Renato Costi; Mohamed Said Sbai-Idrissi; Claude Smadja
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

3.  Ratio of hepatic arterial flow to recipient body weight predicts biliary complications after deceased donor liver transplantation.

Authors:  Peter T W Kim; Giovanna Saracino; Linda Jennings; Michael Ramsay; Gregory J McKenna; Giuliano Testa; Tiffany L Anthony; Nicholas Onaca; Richard M Ruiz; Robert M Goldstein; Marlon F Levy; Goran B Klintmalm
Journal:  HPB (Oxford)       Date:  2014-07-18       Impact factor: 3.647

Review 4.  Idiopathic Non-Cirrhotic Portal Hypertension and Porto-Sinusoidal Vascular Disease: Review of Current Data.

Authors:  Michel Kmeid; Xiuli Liu; Samuel Ballentine; Hwajeong Lee
Journal:  Gastroenterology Res       Date:  2021-04-21

5.  The impact of hepatic steatosis on portal hypertension.

Authors:  Georg Semmler; Bernhard Scheiner; Philipp Schwabl; Theresa Bucsics; Rafael Paternostro; David Chromy; Albert Friedrich Stättermayer; Michael Trauner; Mattias Mandorfer; Arnulf Ferlitsch; Thomas Reiberger
Journal:  PLoS One       Date:  2019-11-06       Impact factor: 3.240

6.  Representative Sinusoids for Hepatic Four-Scale Pharmacokinetics Simulations.

Authors:  Lars Ole Schwen; Arne Schenk; Clemens Kreutz; Jens Timmer; María Matilde Bartolomé Rodríguez; Lars Kuepfer; Tobias Preusser
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

7.  Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features.

Authors:  Luisa Vonghia; Thea Magrone; An Verrijken; Peter Michielsen; Luc Van Gaal; Emilio Jirillo; Sven Francque
Journal:  PLoS One       Date:  2015-11-24       Impact factor: 3.240

8.  Establishment of a reversible model of prehepatic portal hypertension in rats.

Authors:  Xin Zhao; Jian Dou; Qing-Jun Gao
Journal:  Exp Ther Med       Date:  2016-05-30       Impact factor: 2.447

9.  Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease.

Authors:  Bernhard Scheiner; Lisa Steininger; Georg Semmler; Lukas W Unger; Philipp Schwabl; Theresa Bucsics; Rafael Paternostro; Arnulf Ferlitsch; Michael Trauner; Thomas Reiberger; Mattias Mandorfer
Journal:  Liver Int       Date:  2018-09-22       Impact factor: 5.828

Review 10.  Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension.

Authors:  Wolfgang Kreisel; Denise Schaffner; Adhara Lazaro; Jonel Trebicka; Irmgard Merfort; Annette Schmitt-Graeff; Peter Deibert
Journal:  Int J Mol Sci       Date:  2020-08-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.